Immune Signatures of Psoriasis: Comparison of Genetic Expression Profiles in Psoriasis Patients After Therapy with Biologic Agents

May 2015 in “ Journal of The American Academy of Dermatology ”

psoriasis adalimumab ustekinumab Psoriasis Area and Severity Index PASI inflammation interferon response neutrophils biologic agents genetic expression profiles blood microarray biomarkers Humira Stelara

Studysummary This study suggests that blood microarray biomarkers may help predict individual treatment response in psoriasis patients, highlighting a distinct blood signature related to inflammation, interferon, and myeloid lineage transcripts.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer ·

View this study on jaad.org →

Discuss this study in the Community →

Similar Research

5 / 1000+ results

research Challenging Regional Psoriasis and Ustekinumab Biotherapy: Impact of the Patterns of Disease

6 citations , January 2012 in “Journal of Biomedicine and Biotechnology”

This report reviews peer-reviewed case studies indicating potential efficacy of ustekinumab for treating challenging forms of psoriasis but notes the need for further research on cost-effectiveness and risk-benefit.

research Advances in the Molecular Pathogenesis and Targeted Therapy of Psoriasis

May 2025 in “Galen Medical Journal”

This research highlights advancements in understanding and treating psoriasis, finding that targeted therapies like IL-17 and IL-23 inhibitors show promise, but challenges such as adverse events, treatment resistance, and the need for personalized approaches remain.

Anti-TNF Antibody-Induced Psoriasiform Skin Lesions in Patients with Inflammatory Bowel Disease Are Characterised by Interferon-γ-Expressing Th1 Cells and IL-17A/IL-22-Expressing Th17 Cells and Respond to Anti-IL-12/IL-23 Antibody Treatment

research Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment

278 citations , March 2013 in “Gut”

In this study, nearly 5% of anti-TNF-treated patients with IBD developed psoriasiform skin lesions, with smoking identified as a main risk factor, and ustekinumab proved highly effective in severe cases.

Humoral Immune Response to COVID-19 Vaccination in Psoriasis Patients on Biologic Therapy Is Impaired Compared to Healthy Controls

research 224 Humoral immune response to COVID-19 vaccination in psoriasis patients on biologic therapy is impaired compared to healthy controls

April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology”

This study found that psoriasis patients on biologic therapy had significantly lower anti-COVID19 IgG antibody levels after vaccination compared to healthy individuals not on biologic treatment.

research Impact of ustekinumab on quality of life and sexual difficulties associated with psoriasis: Results from phase III clinical trials

February 2010 in “Journal of The American Academy of Dermatology”

This study found that nonobese women with idiopathic hirsutism exhibited lower nitrite/nitrate concentrations and higher fibrinogen levels compared to control subjects, but these were similar to levels in women with polycystic ovary syndrome.